583 related articles for article (PubMed ID: 19192957)
1. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
3. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
5. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
6. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
[TBL] [Abstract][Full Text] [Related]
7. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Harwood KV
Clin J Oncol Nurs; 2004 Dec; 8(6):629-37. PubMed ID: 15637958
[TBL] [Abstract][Full Text] [Related]
8. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
10. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
11. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
14. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
15. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
16. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
Howell A; Dowsett M
Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Buzdar AU; Robertson JF
Ann Pharmacother; 2006 Sep; 40(9):1572-83. PubMed ID: 16912252
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy of advanced disease: analysis and implications of the existing data.
Pritchard KI
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
[TBL] [Abstract][Full Text] [Related]
19. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
